Abstract:Regardless of the unprecedented progress in malignant melanoma treatment strategies and clinical outcomes of patients during the last twelve years, this skin cancer remains the most lethal one. We have previously documented that vitamin D and its low-calcaemic analogues enhance the anticancer activity of drugs including a classic chemotherapeutic—dacarbazine—and an antiangiogenic VEGFRs inhibitor—cediranib. In this study, we explored the response of A375 and RPMI7951 melanoma lines to CPL304110 (CPL110), a novel selective inhibitor of fibroblast growth factor receptors (FGFRs), and compared its efficacy with that of AZD4547, the first-generation FGFRs selective inhibitor. We also tested whether 1,25(OH)2D3, the active form of vitamin D, modulates the response of the cells to these drugs. CPL304110 efficiently decreased the viability of melanoma cells in both A375 and RPMI7951 cell lines, with the IC50 value below 1 μM. However, the metastatic RPMI7951 melanoma cells were less sensitive to the tested drug than A375 cells, isolated from primary tumour site. Both tested FGFR inhibitors triggered G0/G1 cell cycle arrest in A375 melanoma cells and increased apoptotic/necrotic SubG1 fraction in RPMI7951 melanoma cells. 1,25(OH)2D3 modulated the efficacy of CPL304110, by decreasing the IC50 value by more than 4-fold in A375 cell line, but not in RPMI7951 cells. Further analysis revealed that both inhibitors impact vitamin D signalling to some extent, and this effect is cell line-specific. On the other hand, 1,25(OH)2D3, have an impact on the expression of FGFR receptors and phosphorylation (FGFR-Tyr653/654). Interestingly, 1,25(OH)2D3 and CPL304110 co-treatment resulted in activation of the ERK1/2 pathway in A375 cells. Our results strongly suggested possible crosstalk between vitamin D-activated pathways and activity of FGFR inhibitors, which should be considered in further clinical studies.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the effect of fibroblast growth factor receptor inhibitors (FGFR inhibitors) on the proliferation of melanoma cell lines and to study whether vitamin D can modulate the activity of these drugs. Specifically, the researchers tested the effects of the new selective FGFR inhibitor CPL304110 and the first - generation FGFR - selective inhibitor AZD4547 in two melanoma cell lines, A375 and RPMI7951, and analyzed whether the active form of vitamin D (1,25(OH)₂D₃) can modulate the effects of these drugs. The research background mentions that, despite unprecedented progress in the treatment strategies for malignant melanoma and the clinical outcomes of patients, this skin cancer is still one of the most deadly. The researchers have previously demonstrated that vitamin D and its hypocalcemic analogs can enhance the activity of certain anticancer drugs, including the classic chemotherapeutic drug dacarbazine and the anti - angiogenic VEGFRs inhibitor cediranib. Therefore, this study further explored the potential role of vitamin D in the treatment of melanoma with FGFR inhibitors. Through experiments, the researchers found that CPL304110 significantly reduced the viability of A375 and RPMI7951 melanoma cells, with an IC₅₀ value lower than 1 µM. However, the metastatic RPMI7951 melanoma cells were less sensitive to the tested drugs than the A375 cells from the primary tumor site. Both of the tested FGFR inhibitors caused G₀/G₁ - phase cell - cycle arrest in A375 melanoma cells and increased the proportion of apoptotic/necrotic SubG₁ - phase cells in RPMI7951 melanoma cells. 1,25(OH)₂D₃ modulated the effect of CPL304110, reducing the IC₅₀ value by more than 4 - fold in the A375 cell line, but this effect was not observed in RPMI7951 cells. Further analysis showed that these two inhibitors affected the vitamin D signaling pathway to some extent, and this effect was cell - line - specific. In addition, 1,25(OH)₂D₃ affected the expression and phosphorylation of FGFR receptors (FGFR - Tyr⁶⁵³/⁶⁵⁴). Interestingly, the combination of 1,25(OH)₂D₃ and CPL304110 activated the ERK1/2 pathway in A375 cells. In conclusion, this study provides insights into the possible interactions between FGFR inhibitors and vitamin D, which are of great significance for future clinical research.

Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and their Activity Is Modulated by Vitamin D

Anticancer Activity of Vitamin D, Lumisterol and Selected Derivatives against Human Malignant Melanoma Cell Lines

Oxyfadichalcone C Inhibits Melanoma A375 Cell Proliferation and Metastasis Via Suppressing PI3K/Akt and MAPK/ERK Pathways

Fibroblast Growth Factor Receptor Signaling in Skin Cancers

Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model

Knocking out the Vitamin D Receptor Enhances Malignancy and Decreases Responsiveness to Vitamin D3 Hydroxyderivatives in Human Melanoma Cells

New vitamin D analogs as potential therapeutics in melanoma

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma

Antiproliferative effects of LY-2183240 combined with various chemotherapeutic drugs in an isobolographic in vitro model of malignant melanoma

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

Dimethyl Fumarate Combined With Vemurafenib Enhances Anti-Melanoma Efficacy via Inhibiting the Hippo/YAP, NRF2-ARE, and AKT/mTOR/ERK Pathways in A375 Melanoma Cells

Targeting the energy metabolism of melanoma cells: FX-11 acts as a mitochondrial uncoupler

Effect of Tryptophan-Derived AhR Ligands, Kynurenine, Kynurenic Acid and FICZ, on Proliferation, Cell Cycle Regulation and Cell Death of Melanoma Cells—In Vitro Studies

Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism

Modulating the activity of fluoropyrimidines against colorectal cancer by Vitamin D and its analogs

Targeting Mitochondria in Melanoma

Pharmacological inhibition of PDGF-C/neuropilin-1 interaction: A novel strategy to reduce melanoma metastatic potential

Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance